In part, the present disclosure is directed to derivatives of (E)-N-methy1-N-(( 3-methylta 1,8-naphthyndin-3-y1)acrylamide compounds with significant solubility, solid state stability and bioavailability profiles. Said compounds have been found to be effective inhibitors of bacterial fatty acid metabolism via the effective inhibition of FabL hi addition, certain compounds are shown to be stable towards gamma radiation sterilization treatments, and are thus well-suited to the production of a sterile formulation for use in the treatment of illnesses caused by bacterial infections.La présente invention concerne, pour partie, des dérivés de type promédicament de composés de type (E)-N-méthyl-N-((3-méthylbenzofuran-2-yl) méthyl)-3-(7-oxo-5,6,7,8-tetrahydro-l,8-naphtyridin-3-yl)acrylamide présentant des profils de solubilité et de biodisponibilité intéressants.
